Weight-loss drug users taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) are being warned about a rare but serious health risk. The article does not specify which symptoms or risk are involved based on the available excerpt.

• •Users of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) warned of a 'rare but serious' risk
• •No symptoms or specific risk details are available in the source excerpt

• •Doctors warn against using a fake drug for weight loss
• •Warning involves retatrutide, which is not approved

• •Compounded tirzepatide may be linked to reactions at dermal filler sites

Teenagers are buying illegal peptides on the black market to lose weight and tan their skin, thinking it's an easy shortcut. The trend raises safety concerns because these unregulated drugs are not made under medical supervision and their contents are unknown.

• •Teens are buying black market peptides to lose weight and tan their skin
• •The drugs are not made under medical supervision
• •Contents of the unregulated peptides are unknown

• •FDA flagged a liver failure report linked to an Eli Lilly GLP-1 drug
• •Lilly stock moved on the news

Doctors warn that people taking semaglutide (Ozempic and Wegovy) may regain weight within 18 months of stopping the drug. The warning highlights that weight loss from these medications is often temporary without ongoing use.

• •Doctors warn of weight regain within 18 months of stopping semaglutide
• •Warning applies to both Ozempic and Wegovy users
• •Weight loss from the drug is often temporary without continued use

• •A liver failure signal linked to Lilly's Foundayo pushed shares down
• •Analysts say they are not worried about the safety blip

A Texas doctor was convicted for illegally selling over a million pills without prescriptions. A separate study found that semaglutide, a weight-loss drug, may reduce heavy drinking in people who take it.

• •Study found semaglutide may cut heavy drinking in users
• •Texas doctor convicted for selling over a million pills illegally

Doctors say semaglutide (Ozempic and Wegovy) can cause temporary hair loss in some people who take it. The hair loss appears to be a side effect that goes away over time.

• •Doctors link semaglutide (Ozempic, Wegovy) to temporary hair loss in some patients
• •The hair loss is described as a side effect that resolves over time

A lawsuit claims semaglutide (Ozempic) caused vision loss in patients through a condition called NAION (nerve damage in the eye). The case highlights a potential safety problem being raised in courts against the weight-loss drug.

• •Lawsuit claims Ozempic caused vision loss tied to NAION eye nerve damage
• •Case targets semaglutide, Novo Nordisk's weight-loss and diabetes drug

• •Law firm page tracks Mounjaro eye side effect lawsuits
• •Update tagged for 2026

A South Carolina resident filed a lawsuit claiming that Ozempic (semaglutide) caused a permanent eye condition called NAION. The lawsuit was brought by law firm Parker Waichman LLP.

• •South Carolina resident sued over Ozempic use
• •Lawsuit claims the drug caused NAION, a permanent eye condition
• •Parker Waichman LLP filed the case

Lawsuits are being filed against Novo Nordisk over Wegovy, claiming the weight-loss drug causes a stomach problem called gastroparesis. The legal cases may lead to settlements if claims that the drug causes lasting stomach damage are proven.

• •Lawsuits target Novo Nordisk over Wegovy
• •Claims say the drug causes gastroparesis, a stomach problem
• •Cases may lead to settlements if lasting harm is proven

• •A patient says they developed a health condition while taking Mounjaro.
• •Mounjaro is Eli Lilly's tirzepatide weight-loss and diabetes drug.

A judge threw out part of Eli Lilly's lawsuit against Empower Pharmacy, a Houston pharmacy that makes copies of weight-loss drugs like semaglutide. The ruling suggests Lilly's case against the compounding pharmacy faces legal obstacles.

• •Judge dismissed part of Eli Lilly's lawsuit against Empower Pharmacy
• •Empower is a Houston compounding pharmacy making copies of GLP-1 drugs
• •Case targets compounded versions of weight-loss drugs like semaglutide

A medical case report describes a patient who developed high blood calcium levels while taking tirzepatide (a diabetes and weight-loss drug) and taking calcium supplements. Doctors said the combination of the drug and extra calcium caused the problem.

• •Case report describes hypercalcemia in a patient on tirzepatide
• •Patient was also taking calcium supplements
• •Authors tie the high calcium to the drug-supplement combination

Eli Lilly warned people in India's Haryana state to buy tirzepatide only with a prescription, after authorities found fake versions of the drug. The company is trying to stop people from buying counterfeit copies that could be harmful.

• •Authorities in Haryana, India found fake tirzepatide on the market
• •Eli Lilly told buyers to only get tirzepatide with a prescription
• •Lilly issued the warning to fight counterfeit versions of the drug

A judge threw out part of Eli Lilly's lawsuit against Empower Pharmacy, a Houston pharmacy that makes copy-cat versions of weight-loss drugs. The ruling limits what claims Eli Lilly can pursue in its case.

• •Judge dismissed part of Eli Lilly's lawsuit against Empower Pharmacy
• •Empower is a Houston pharmacy making compounded GLP-1 drugs
• •Ruling narrows the claims Lilly can pursue against the compounder

Early reports suggest Wegovy (semaglutide) may be linked to a rare type of stroke that affects the eye. Doctors are still studying whether the weight-loss drug actually causes this problem or if it just happens to people who use it.

• •Early data links Wegovy (semaglutide) to risk of a rare 'eye stroke'
• •Doctors are still studying if the drug causes the problem or not

• •Case report describes mixed medullary and papillary thyroid carcinoma in a tirzepatide patient
• •Published in Cureus journal
• •Tirzepatide carries a boxed warning for thyroid C-cell tumors

Medical News Today looked at whether Wegovy (a weight-loss drug based on semaglutide) is safe to use long-term. The article examines safety questions people have about taking this drug over months or years.

• •Medical News Today reviewed long-term safety of Wegovy
• •Wegovy is a weight-loss drug based on semaglutide

Doctors and patients report that semaglutide (Ozempic) and other GLP-1 drugs may cause emotional flattening, a condition some call 'Ozempic Personality'. The report examines whether this side effect is real and how common it might be.

• •Doctors and patients report emotional flattening on semaglutide and other GLP-1 drugs
• •Some are calling the effect 'Ozempic Personality'
• •Report asks if the side effect is real and how often it happens